Lung Cancer

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some patients with non-small cell lung cancer.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

Through cancer and life’s challenges, having and showing gratitude changed everything for me.

For patients with extensive-stage small cell lung cancer, Loqtorzi was shown to improve progression-free survival and overall survival.

Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.

Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of radiotherapy to TKI treatment.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

In patients with advanced NSCLC, treatment with Jemperli plus chemotherapy showed promising effectiveness compared with Keytruda plus chemotherapy.

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant non-small cell lung cancer.

Ponsegromab helped patients with cachexia and elevated GDF-15 levels gain weight, increase activity and improve cachexia symptoms, with manageable safety.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

After cancer treatment, I wanted to go right back to living my life normally, but a fellow CURE blogger’s post reminded me that rest is necessary too.

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with minimal side effects.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

During my lung cancer journey, I learned a few important ways to help me lessen the apprehension I felt, including meditation.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

As someone who disliked pink for years, it has grown on me over time, especially after having breast cancer.

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and following chemotherapy.

Two patients reflected on how extraordinary their oncology nurses are — even noting that they forget about their cancer when talking with their nurses.

Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for immunotherapy.

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal metastases in patients with EGFR-variant NSCLC.

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is as effective as in-person care.